Logo image
New search Research units
Sign in
Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy
Journal article   Peer reviewed

Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy

Alexander Diamantopoulos, Maurizio Benucci, Stefano Capri, Wolfgang Berger, Neil Wintfeld, Giovanni Giuliani and Walter Ricciardi
Journal of medical economics, Vol.15(3), pp.576-585
2012
PMID: 22313326

Abstract

Cost-effectiveness Cost-utility analysis Disease-modifying anti-rheumatic drugs Health related quality of life Pharmacoeconomic modeling Rheumatoid arthritis Tocilizumab (additional) biologics Disease severity Standard of care Treatment-related costs
This study was designed to evaluate the cost utility of tocilizumab in rheumatoid arthritis (RA) patients, with inadequate responses to traditional disease-modifying anti-rheumatic drugs (tDMARDs) from a payer’s perspective in Italy.
pdf
991001031579005126396.79 kB
Published (Version of record)Ask the Library / Chiedi alla Biblioteca Restricted Access
url
https://doi.org/10.3111/13696998.2012.665110View
Published (Version of record) Open

Details

Logo image